SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of MacroGenics, Inc.

NEW YORK, 24 June 2024 /PRNewswire/ — Pomerantz LLP is investigating claims on behalf of investors in MacroGenics, Inc. (“MacroGenics” or the “Company”) (NASDAQ: MGNX). Such investors are advised to contact Danielle Peyton at (email protected) or 646-581-9980, extension 7980.

The investigation concerns whether MacroGenics and certain of its officers and/or directors engaged in securities transactions. Fraud or other unlawful business practices.

(Click here for information on joining the class action lawsuit.)

At 3 April 2024MacroGenics announced interim safety data from Phase 2 TAMARACK as contained in the summary submitted to the American Society of Clinical Oncology on February 6, 2024The company reported that “(p)eriminal safety data from TAMARACK suggest that reducing the dose and frequency of Vobra Duo improves safety and tolerability in men with mCRPC.” Then, on May 10, 2024MacroGenics announced that five patients in the TAMARACK study had died.

Following this news, MacroGenics’ share price fell $11.36 per share or 77.4% and closed at $3.31 per share on May 10, 2024.

Pomerantz LLP, with offices in new York, Chicago, Los Angeles, London, ParisAnd Tel-Avivis considered one of the leading law firms in the areas of corporate, securities and antitrust litigation. Founded by the late Abraham L. PomerantzKnown as the dean of class action lawyers, Pomerantz was a pioneer in the field of securities class action litigation. Today, more than 85 years later, Pomerantz continues the tradition he established and fights for the rights of victims of securities class action litigation. FraudBreach of fiduciary duty and corporate misconduct. The firm has won billions of dollars in damages on behalf of class action plaintiffs. See www.pomlaw.com.

Attorney advertising. Past results do not guarantee similar results.

CONTACT:
Danielle Peyton
Pomerantz LLP
(email protected)
646-581-9980 extension 7980

Never miss a story from Pomerantz LLP again.